Media coverage about Cynosure (NASDAQ:CYNO) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cynosure earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.1106616741828 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Anukreethy Vas from Tamil Nadu crowned Miss India World 2018 (dekhnews.com)
- Children take part in aksharabhyasam (thehindu.com)
- SOTY 2: Tiger is cynosure of Ananya, Tara’s eyes, but for whom does his heart beat? (asianage.com)
- Take me to Igbomina land (2) (thenationonlineng.net)
- Tattoo Removal : CAGR of 15.85% during the period 2017-2021 | Cutera, Cynosure, Lumenis, Syneron Medical (openpr.com)
Shares of Cynosure remained flat at $$66.00 during trading hours on Wednesday, Marketbeat Ratings reports. Cynosure has a 52 week low of $39.90 and a 52 week high of $66.65. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.54 and a current ratio of 3.28.
Cynosure Company Profile
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
Receive News & Ratings for Cynosure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure and related companies with MarketBeat.com's FREE daily email newsletter.